Related Experiment Videos
Left ventricular hypertrophy in end-stage renal disease
J D Harnett1, P S Parfrey, S M Griffiths
1Division of Nephrology, Memorial University, St. John's, Nfld.
Nephron
|January 1, 1988
Summary
Left ventricular hypertrophy (LVH) affects over half of end-stage renal disease (ESRD) patients. Dialysis treatment, age, and hypertension are key risk factors for LVH in ESRD.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) is a common complication in end-stage renal disease (ESRD) patients.
- Identifying risk factors for LVH is crucial for managing cardiovascular health in this population.
Purpose of the Study:
- To determine the prevalence of LVH in non-diabetic ESRD patients.
- To identify independent risk factors associated with LVH in ESRD patients.
Main Methods:
- Echocardiography and clinical review were performed on 189 non-diabetic ESRD patients.
- Multiple logistic regression analysis was used to identify independent risk factors for LVH.
Main Results:
- 55% of ESRD patients exhibited LVH.
- Independent risk factors for LVH included dialysis treatment, older age, hypertension, and high serum alkaline phosphatase.
- In severe LVH cases, high serum alkaline phosphatase, high diastolic blood pressure, and age were significant predictors.
Conclusions:
- LVH is highly prevalent in ESRD patients.
- Dialysis treatment, age, hypertension, and elevated alkaline phosphatase are significant risk factors for LVH in ESRD.
- Management strategies should address these risk factors to mitigate cardiovascular risk.